RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

Learn more about:
Related Clinical Trial
A Study to Improve the Awareness of Mucopolysaccharidosis Type II in Brazil Long-term Follow-Up for RGX-121 Mucopolysaccharidosis Type II Observational A Phase Ⅲ Study of JR-141 in Patients With Mucopolysaccharidosis II RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094 An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Safety and Efficacy of Hunterase Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701) A Study of GC1111 in Hunter Syndrom Patients Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome) A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723 Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II Study of Idursulfase-beta (GC1111) in Hunter Syndrome A Study of JR-141 in Patients With Mucopolysaccharidosis II A Study of JR-141 in Patients With Mucopolysaccharidosis II An Extension Study of JR-141 in Patients With Mucopolysaccharidosis II A Study of JR-141 in Patients With Mucopolysaccharidosis Type II The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients Hunter Outcome Survey (HOS) Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase® Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome Mucopolysaccharidosis Type II Natural History Biomarkers for Hunter Syndrome RGX-121 Gene Therapy in Patients With MPS II (Hunter Syndrome) Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II) A Study of DNL310 in Pediatric Subjects With Hunter Syndrome Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II) Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age A Study of Potential Treatment-Responsive Biomarkers in Hunter Syndrome

Recruitment Information


Administrative Informations